section name header

Pronunciation

am-oh-BAR-bi-tal

Classifications

Therapeutic Classification: sedative/hypnotics

Pharmacologic Classification: barbiturates

Indications

BEERS REMS


Unlabeled Use:
  • Psychiatric interviews.
  • Wada testing (intracarotid administration to determine hemispheric locus of language dominance prior to epilepsy surgery).

Action

  • Produces all levels of CNS depression:
    • Depresses sensory cortex,
    • Decreases motor activity,
    • Alters cerebral function.
  • Inhibits transmission in the CNS and raises seizure threshold.
Therapeutic effects:
  • Hypnosis.
  • Sedation.

Pharmacokinetics

Absorption: Well absorbed after IM administration.

Distribution: Rapidly and widely distributed; concentrates in brain, liver, and kidneys. Readily crosses placenta; small amounts enter breast milk. Moderately bound to plasma proteins.

Metabolism/Excretion: Mostly metabolized by the liver.

Half-Life: 16–40 hr.

Time/Action Profile

(sedation)

ROUTEONSETPEAKDURATION
IM30–45 minrapid6–8 hr
IVseveral minrapid6–8 hr





Contraind./Precautions

Contraindicated in:

Use Cautiously in:

Adv. Reactions/Side Effects

Neuro: drowsiness, abnormal thinking, agitation, ataxia, CNS depression, confusion, dizziness, headache, nightmares, vertigo

Resp: BRONCHOSPASM (IV ONLY), LARYNGOSPASM (IV ONLY), apnea, respiratory depression

CV: bradycardia, hypotension, syncope

GI: constipation, nausea, vomiting

Derm: ANGIOEDEMA, exfoliative dermatitis, purpura, rash

Local: pain or sterile abscess at IM site, phlebitis at IV site

MS: hyperkinesia

Misc: STEVENS-JOHNSON SYNDROMEHYPERSENSITIVITY REACTIONS INCLUDING , fever

Interactions

Drug-drug:

Drug-Natural Products:

Route/Dosage

Availability

(Generic available)

Assessment

Implementation

IV Administration:

Patient/Family Teaching

Evaluation/Desired Outcomes

US Brand Names

Amytal

Contr. Subst. Schedule

Schedule II (C-II)

Pot. Nursing Diagnoses